| Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab C Nicolazzo, C Raimondi, ML Mancini, S Caponnetto, A Gradilone, ... Scientific reports 6 (1), 31726, 2016 | 251 | 2016 |
| MGL receptor and immunity: when the ligand can make the difference IG Zizzari, C Napoletano, F Battisti, H Rahimi, S Caponnetto, L Pierelli, ... Journal of Immunology Research 2015, 2015 | 68 | 2015 |
| Adjuvant chemotherapy in resected colon cancer: when, how and how long? AJ Gelibter, S Caponnetto, F Urbano, A Emiliani, S Scagnoli, ... Surgical Oncology 30, 100-107, 2019 | 66 | 2019 |
| In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells M Donia, D Maksimovic-Ivanic, S Mijatovic, M Mojic, D Miljkovic, ... Cell Cycle 10 (3), 492-499, 2011 | 57 | 2011 |
| TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway IG Zizzari, C Napoletano, A Botticelli, S Caponnetto, F Calabrò, A Gelibter, ... Cancer immunology research 6 (6), 711-722, 2018 | 48 | 2018 |
| Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. A Nicoletti, P Fagone, G Donzuso, K Mangano, V Dibilio, S Caponnetto, ... Cytokine 55 (2), 165-167, 2011 | 48 | 2011 |
| Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial M Antonilli, H Rahimi, V Visconti, C Napoletano, I Ruscito, IG Zizzari, ... International journal of oncology 48 (4), 1369-1378, 2016 | 29 | 2016 |
| Burned-out testicular cancer: really a different history C Mosillo, S Scagnoli, G Pomati, S Caponnetto, ML Mancini, M Bezzi, ... Case reports in oncology 10 (3), 846-850, 2018 | 25 | 2018 |
| Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: real-world data from an Italian managed access program M Prisciandaro, R Ratta, F Massari, G Fornarini, S Caponnetto, R Iacovelli, ... American journal of clinical oncology 42 (1), 42-45, 2019 | 21 | 2019 |
| The macrophage galactose-type C-type lectin (MGL) modulates regulatory T cell functions IG Zizzari, P Martufi, F Battisti, H Rahimi, S Caponnetto, F Bellati, M Nuti, ... PLoS One 10 (7), e0132617, 2015 | 21 | 2015 |
| Prolactin as a potential early predictive factor in metastatic non-small cell lung cancer patients treated with nivolumab S Caponnetto, GM Iannantuono, G Barchiesi, V Magri, A Gelibter, ... Oncology 93 (1), 62-66, 2017 | 20 | 2017 |
| Exploratory pilot study of circulating biomarkers in metastatic renal cell carcinoma IG Zizzari, C Napoletano, A Di Filippo, A Botticelli, A Gelibter, F Calabrò, ... Cancers 12 (9), 2620, 2020 | 19 | 2020 |
| Impact of sarcopenia and inflammation on patients with advanced non-small cell lung cancer (NCSCL) treated with immune checkpoint inhibitors (ICIs): a prospective study M Tenuta, A Gelibter, C Pandozzi, G Sirgiovanni, F Campolo, MA Venneri, ... Cancers 13 (24), 6355, 2021 | 17 | 2021 |
| Cancer immunotherapy in patients with brain metastases S Caponnetto, A Draghi, TH Borch, M Nuti, E Cortesi, IM Svane, M Donia Cancer Immunology, Immunotherapy 67, 703-711, 2018 | 16 | 2018 |
| Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci Rep. 2016; 6: 31726 C Nicolazzo, C Raimondi, M Mancini, S Caponnetto, A Gradilone, ... DOI: https://doi. org/10.1038/srep31726, 31726, 0 | 14 | |
| Immunological and clinical impact of cancer stem cells in vulvar cancer: role of CD133/CD24/ABCG2-expressing cells C Napoletano, F Bellati, I Ruscito, M Pernice, IG Zizzari, S Caponnetto, ... Anticancer research 36 (10), 5109-5116, 2016 | 13 | 2016 |
| HE3286, an orally bioavailable synthetic analogue of an active DHEA metabolite suppresses spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse MM Kosiewicz, DL Auci, P Fagone, K Mangano, S Caponnetto, CF Tucker, ... European journal of pharmacology 658 (2-3), 257-262, 2011 | 11 | 2011 |
| CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies R Moretto, D Rossini, V Conca, S Lonardi, C Rasola, C Antoniotti, ... British Journal of Cancer 125 (6), 839-845, 2021 | 10 | 2021 |
| Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO D Rossini, S Lonardi, C Antoniotti, D Santini, G Tomasello, P Ermacora, ... British Journal of Cancer 124 (1), 183-190, 2021 | 10 | 2021 |
| Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer C Nicolazzo, F Loreni, S Caponnetto, V Magri, AR Vestri, R Zamarchi, ... Oncotarget 11 (45), 4115, 2020 | 10 | 2020 |
